Nuvectis Pharma NVCT 深 沪
等待开盘 09-16 09:30:00 美东时间
21.92
-1.430
-6.12%
华盛通- 最 高23.01
- 今 开23.00
- 成交量 16.61万股
- 最 低 21.78
- 昨 收 23.35
- 总市值 7.16亿
- 52周最高 29.275
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.55
- 委 比 -29.82%
- 总股本 3264.41万
- 历史最高 29.275
- 量 比 1.00
- 振 幅 5.27%
- 历史最低 3.08
- 每 手 1
- 风险率 5.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvectis Pharma To Participate in Upcoming Investor Conferences
Nuvectis Pharma, Inc. announced that its senior management will participate in two upcoming investor conferences: the 2026 Cantor Global Healthcare Conference on September 11, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company, focused on developing innovative therapies for complement-related conditions and oncology, highlighted its lead drug candidate, ciprocopan, recently approved in China ...
09-03 12:00
Nuvectis Pharma Launches New $200 Million ATM Program
Nuvectis Pharma ( ($NVCT) ) has shared an announcement. On August 21, 2026, Nuv...
08-22 04:59
Nuvectis Pharma Files Base Prospectus Related To The Offer And Sale Of Up To $200M Of Securities
Nuvectis Pharma Files Base Prospectus Related To The Offer And Sale Of Up To $200M Of Securities
08-22 04:43
Nuvectis Pharma reports results
Nuvectis Pharma press release (NVCT): The Company's net loss was $7.0 million for the three months ended June 30, 2026, compared to $6.3 million for the three months ended June 30, 2025, an increase i...
08-05 00:56
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is unchanged from the same period last year.
08-04 20:03
Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria
Nuvectis Pharma, Inc. (NASDAQ:NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Fac...
07-23 19:31
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - July 6 Vo...
07-04 03:00
Why AeroVironment Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Shares of AeroVironment, Inc. (NASDAQ:AVAV) rose sharply in pre-market trading after the company reported better-than-expected financial results for the fourth quarter of fiscal 2026. AeroVironment guided for fiscal 2027 revenue of approximately $2.13 billion to $2.23 billion, versus estimates of $2...
06-30 18:10
Nuvectis Pharma（NVCT）完成稀释性二次公开发行后 盘前股价下跌16.75%
生物制药公司Nuvectis Pharma（股票代码：NVCT）完成500万股稀释性二次公开发行定价，发行价为每股20.00美元，较前一交易日28.53美元的收...
06-30 16:26
